Determination and prediction of risks being obesity and diabetes mellitus treatment of schizophrenic patients by atypical antipsychotics

Tohru Yoshizawa, Hiroki Yamada, Kentaro Horiuchi, Masao Nakahara, Masayuki Tani, Yuko Takayama, Akira Iwanami, Nobumasa Kato, Mitsugu Hachisu, Toshinori Yamamoto, Masaru Mimura, Yasuko Nakano

Research output: Contribution to journalArticle

Abstract

Atypical antipsychotics are used as first-line treatment of schizophrenia, because of less side effects of extrapyramidal tract and having effect on negative symptoms comparing to typical antipsychotics. However, atypical antipsychotics show side effects of body weight gain and impaired glucose tolerance. We studied effects of olanzapine and blonanserine on schizophrenic patients with indices of changes of blood adiponectine and retinol binding protein 4 (RBP4). Adiponectine shows activities of antidiabetes, antiarteriosclerosis and antiinflammation and the blood protein contents are reduced by impaired of lipid metabolism. On the other hand, RBP4 increases an insulin resistant and the blood protein concentration is increased by the lipid metabolism abnormality. Drugs are prescribed to the patients with clinical dosage regimen and combination of antipsychotic is avoided. By a treatment of olanzapine, time course change of adiponectine and RBP4 showed mirror image, i.e. adiponectine increased and RBP4 decereased at initial treatment and then went recovering with the time of treatment. Blonanserine did not show clear influence to these proteins. Olanzapine increased body weight and BMI with treating after 14 weeks, while blonanserine did not. Urine C-peptide concentration reflecting a secretion of insulin was markedly decreased by olanzapine, while slightly decreased by blonanserine. However, there were no significant difference between olanzapine and blonanserine on the effect of urine C-peptide consentration. Blood glucose level, % of hemoglobine Alc and % of glycoalbumine were not changed by both antipsychotics. These results possibly indicate that olanzapine increases body weight and BMI with worsening lipid metabolism and also impairs glucose torelability by reducing insulin secretion, while blonanserine did not show clear influence on lipid metabolism and glucose torelability.

Original languageEnglish
Pages (from-to)468-478
Number of pages11
JournalJournal of the Showa Medical Association
Volume76
Issue number4
Publication statusPublished - 2016 Aug 1

Fingerprint

olanzapine
Antipsychotic Agents
Retinol-Binding Proteins
Diabetes Mellitus
Obesity
Lipid Metabolism
C-Peptide
Body Weight
Insulin
Extrapyramidal Tracts
Blood Proteins
Therapeutics
Urine
Glucose
Glucose Intolerance
Weight Gain
Blood Glucose
Schizophrenia

Keywords

  • Atypical antipsychotics
  • Blonanserine
  • Body weight
  • C-peptide
  • HMW-adiponectine
  • Olanzapine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Yoshizawa, T., Yamada, H., Horiuchi, K., Nakahara, M., Tani, M., Takayama, Y., ... Nakano, Y. (2016). Determination and prediction of risks being obesity and diabetes mellitus treatment of schizophrenic patients by atypical antipsychotics. Journal of the Showa Medical Association, 76(4), 468-478.

Determination and prediction of risks being obesity and diabetes mellitus treatment of schizophrenic patients by atypical antipsychotics. / Yoshizawa, Tohru; Yamada, Hiroki; Horiuchi, Kentaro; Nakahara, Masao; Tani, Masayuki; Takayama, Yuko; Iwanami, Akira; Kato, Nobumasa; Hachisu, Mitsugu; Yamamoto, Toshinori; Mimura, Masaru; Nakano, Yasuko.

In: Journal of the Showa Medical Association, Vol. 76, No. 4, 01.08.2016, p. 468-478.

Research output: Contribution to journalArticle

Yoshizawa, T, Yamada, H, Horiuchi, K, Nakahara, M, Tani, M, Takayama, Y, Iwanami, A, Kato, N, Hachisu, M, Yamamoto, T, Mimura, M & Nakano, Y 2016, 'Determination and prediction of risks being obesity and diabetes mellitus treatment of schizophrenic patients by atypical antipsychotics', Journal of the Showa Medical Association, vol. 76, no. 4, pp. 468-478.
Yoshizawa, Tohru ; Yamada, Hiroki ; Horiuchi, Kentaro ; Nakahara, Masao ; Tani, Masayuki ; Takayama, Yuko ; Iwanami, Akira ; Kato, Nobumasa ; Hachisu, Mitsugu ; Yamamoto, Toshinori ; Mimura, Masaru ; Nakano, Yasuko. / Determination and prediction of risks being obesity and diabetes mellitus treatment of schizophrenic patients by atypical antipsychotics. In: Journal of the Showa Medical Association. 2016 ; Vol. 76, No. 4. pp. 468-478.
@article{e3bfd4288d0541ffb8eef2758a9ac1b8,
title = "Determination and prediction of risks being obesity and diabetes mellitus treatment of schizophrenic patients by atypical antipsychotics",
abstract = "Atypical antipsychotics are used as first-line treatment of schizophrenia, because of less side effects of extrapyramidal tract and having effect on negative symptoms comparing to typical antipsychotics. However, atypical antipsychotics show side effects of body weight gain and impaired glucose tolerance. We studied effects of olanzapine and blonanserine on schizophrenic patients with indices of changes of blood adiponectine and retinol binding protein 4 (RBP4). Adiponectine shows activities of antidiabetes, antiarteriosclerosis and antiinflammation and the blood protein contents are reduced by impaired of lipid metabolism. On the other hand, RBP4 increases an insulin resistant and the blood protein concentration is increased by the lipid metabolism abnormality. Drugs are prescribed to the patients with clinical dosage regimen and combination of antipsychotic is avoided. By a treatment of olanzapine, time course change of adiponectine and RBP4 showed mirror image, i.e. adiponectine increased and RBP4 decereased at initial treatment and then went recovering with the time of treatment. Blonanserine did not show clear influence to these proteins. Olanzapine increased body weight and BMI with treating after 14 weeks, while blonanserine did not. Urine C-peptide concentration reflecting a secretion of insulin was markedly decreased by olanzapine, while slightly decreased by blonanserine. However, there were no significant difference between olanzapine and blonanserine on the effect of urine C-peptide consentration. Blood glucose level, {\%} of hemoglobine Alc and {\%} of glycoalbumine were not changed by both antipsychotics. These results possibly indicate that olanzapine increases body weight and BMI with worsening lipid metabolism and also impairs glucose torelability by reducing insulin secretion, while blonanserine did not show clear influence on lipid metabolism and glucose torelability.",
keywords = "Atypical antipsychotics, Blonanserine, Body weight, C-peptide, HMW-adiponectine, Olanzapine",
author = "Tohru Yoshizawa and Hiroki Yamada and Kentaro Horiuchi and Masao Nakahara and Masayuki Tani and Yuko Takayama and Akira Iwanami and Nobumasa Kato and Mitsugu Hachisu and Toshinori Yamamoto and Masaru Mimura and Yasuko Nakano",
year = "2016",
month = "8",
day = "1",
language = "English",
volume = "76",
pages = "468--478",
journal = "Showa Igakkai zasshi = The Journal of the Showa Medical Association",
issn = "0037-4342",
publisher = "Showa Medical Association",
number = "4",

}

TY - JOUR

T1 - Determination and prediction of risks being obesity and diabetes mellitus treatment of schizophrenic patients by atypical antipsychotics

AU - Yoshizawa, Tohru

AU - Yamada, Hiroki

AU - Horiuchi, Kentaro

AU - Nakahara, Masao

AU - Tani, Masayuki

AU - Takayama, Yuko

AU - Iwanami, Akira

AU - Kato, Nobumasa

AU - Hachisu, Mitsugu

AU - Yamamoto, Toshinori

AU - Mimura, Masaru

AU - Nakano, Yasuko

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Atypical antipsychotics are used as first-line treatment of schizophrenia, because of less side effects of extrapyramidal tract and having effect on negative symptoms comparing to typical antipsychotics. However, atypical antipsychotics show side effects of body weight gain and impaired glucose tolerance. We studied effects of olanzapine and blonanserine on schizophrenic patients with indices of changes of blood adiponectine and retinol binding protein 4 (RBP4). Adiponectine shows activities of antidiabetes, antiarteriosclerosis and antiinflammation and the blood protein contents are reduced by impaired of lipid metabolism. On the other hand, RBP4 increases an insulin resistant and the blood protein concentration is increased by the lipid metabolism abnormality. Drugs are prescribed to the patients with clinical dosage regimen and combination of antipsychotic is avoided. By a treatment of olanzapine, time course change of adiponectine and RBP4 showed mirror image, i.e. adiponectine increased and RBP4 decereased at initial treatment and then went recovering with the time of treatment. Blonanserine did not show clear influence to these proteins. Olanzapine increased body weight and BMI with treating after 14 weeks, while blonanserine did not. Urine C-peptide concentration reflecting a secretion of insulin was markedly decreased by olanzapine, while slightly decreased by blonanserine. However, there were no significant difference between olanzapine and blonanserine on the effect of urine C-peptide consentration. Blood glucose level, % of hemoglobine Alc and % of glycoalbumine were not changed by both antipsychotics. These results possibly indicate that olanzapine increases body weight and BMI with worsening lipid metabolism and also impairs glucose torelability by reducing insulin secretion, while blonanserine did not show clear influence on lipid metabolism and glucose torelability.

AB - Atypical antipsychotics are used as first-line treatment of schizophrenia, because of less side effects of extrapyramidal tract and having effect on negative symptoms comparing to typical antipsychotics. However, atypical antipsychotics show side effects of body weight gain and impaired glucose tolerance. We studied effects of olanzapine and blonanserine on schizophrenic patients with indices of changes of blood adiponectine and retinol binding protein 4 (RBP4). Adiponectine shows activities of antidiabetes, antiarteriosclerosis and antiinflammation and the blood protein contents are reduced by impaired of lipid metabolism. On the other hand, RBP4 increases an insulin resistant and the blood protein concentration is increased by the lipid metabolism abnormality. Drugs are prescribed to the patients with clinical dosage regimen and combination of antipsychotic is avoided. By a treatment of olanzapine, time course change of adiponectine and RBP4 showed mirror image, i.e. adiponectine increased and RBP4 decereased at initial treatment and then went recovering with the time of treatment. Blonanserine did not show clear influence to these proteins. Olanzapine increased body weight and BMI with treating after 14 weeks, while blonanserine did not. Urine C-peptide concentration reflecting a secretion of insulin was markedly decreased by olanzapine, while slightly decreased by blonanserine. However, there were no significant difference between olanzapine and blonanserine on the effect of urine C-peptide consentration. Blood glucose level, % of hemoglobine Alc and % of glycoalbumine were not changed by both antipsychotics. These results possibly indicate that olanzapine increases body weight and BMI with worsening lipid metabolism and also impairs glucose torelability by reducing insulin secretion, while blonanserine did not show clear influence on lipid metabolism and glucose torelability.

KW - Atypical antipsychotics

KW - Blonanserine

KW - Body weight

KW - C-peptide

KW - HMW-adiponectine

KW - Olanzapine

UR - http://www.scopus.com/inward/record.url?scp=85015974470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015974470&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85015974470

VL - 76

SP - 468

EP - 478

JO - Showa Igakkai zasshi = The Journal of the Showa Medical Association

JF - Showa Igakkai zasshi = The Journal of the Showa Medical Association

SN - 0037-4342

IS - 4

ER -